NICE plans to lift a restriction on 3 Alzheimer's drugs

10/6/2010 | Reuters

The U.K. National Institute for Health and Clinical Excellence issued a draft guidance that would reverse a 2006 decision to restrict patient access to certain Alzheimer's disease drugs. The agency recommended that Eisai and Pfizer's Aricept, Novartis' Exelon and Shire's Reminyl be covered by the National Health Service for patients with mild and moderate Alzheimer's.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD